I got an email with the following regarding Apalutamide, so I thought to post and share.
MECHANISM OF ACTIONApalutamide is a second generation androgen receptor inhibitor
INDICATIONApalutamide indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
STUDY DESIGN & POPULATIONA global randomized double-blind, placebo-controlled Phase III trial (n=1,207) evaluating Apalutamide vs. placebo in nmCRPC patients at high risk for developing metastases (as defined by PSA doubling-time of ≤10 months and PSA above 2ng/mL):
No prior chemotherapy, immunotherapy, second generation AR antagonist, or CYP17A inhibitor
Ongoing androgen deprivation therapy (ADT) or prior orchiectomy
ECOG 0 or 1
M0 is determined by using bone scan, MRI, and/or CT
DOSING & ADMINISTRATIONApalutamide capsules x 4, administered once daily
PRIMARY ENDPOINTMetastasis-free survival (MFS): 40.5 months for apalutamide vs. 16 months for placebo (increase of 24 months); HR 0.28, p < 0.0001)
OS SECONDARY ENDPOINTOverall survival (OS) data were not mature at the time of final MFS analysis but show a positive trend in OS improvement for apalutamide vs placebo
OTHER SECONDARY EFFICACY ENDPOINTSStatistically significant improvement in time to metastases, progression-free survival, and time to symptomatic progression.
QUALITY OF LIFENo difference between apalutamide and placebo in the time to deterioration in health-related QOL measured by FACT-P and EQ-5D
SAFETYIncidence of All AEs (Apalutamide vs. placebo)
Diarrhea: 20% vs 15%
Nausea: 18% vs 15.8%
Rash: 23.8% vs 5.5%
Fracture: 11.7% vs 6.5%
Hypertension: 24.8% vs 19.8%
Dizziness: 9.3% vs 6.3%
Fall: 15.6% vs 9.0%
Fatigue: 30.4% vs 21.1%
Seizures/convulsions: 0.2% (2 pts.) vs 0%
Mental impairment: 5.1% vs 3.0%
Additional DataIncreased incidence of seizures stated in the Prescribing Information Warning & Precautions section.